ansuvimab
E468967
antiviral drug
biologic medicinal product
human monoclonal antibody
monoclonal antibody
therapeutic antibody
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
All labels observed (1)
| Label | Occurrences |
|---|---|
| ansuvimab canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T4784966 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ansuvimab Context triple: [mAb114, hasFullName, ansuvimab]
-
A.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
B.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ansuvimab Target entity description: Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
-
A.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
B.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
antiviral drug
ⓘ
biologic medicinal product ⓘ human monoclonal antibody ⓘ monoclonal antibody ⓘ therapeutic antibody ⓘ |
| actsOn |
Ebolavirus
ⓘ
Zaire ebolavirus ⓘ |
| administeredAs | single-dose intravenous infusion ⓘ |
| antibodyType | IgG1 ⓘ |
| approvalYear | 2020 ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| ATCCode | J06BD09 ⓘ |
| belongsToClass |
Ebola virus–directed antibodies
ⓘ
antiviral monoclonal antibodies ⓘ |
| clinicalTrialContext | evaluated during Ebola virus disease outbreaks in Africa ⓘ |
| countryOfFirstApproval | United States of America ⓘ |
| developedBy |
Mapp Biopharmaceutical
ⓘ
Ridgeback Biotherapeutics ⓘ |
| distinguishedFrom |
REGN-EB3
ⓘ
ZMapp ⓘ |
| hasMolecularTarget | Ebola virus envelope glycoprotein GP1,2 ⓘ |
| hasTradeName | Ebanga ⓘ |
| indicatedFor |
Ebola virus disease due to Zaire ebolavirus
ⓘ
infection caused by Zaire ebolavirus ⓘ |
| indicationPopulation |
adults with Zaire ebolavirus infection
ⓘ
children with Zaire ebolavirus infection ⓘ |
| isMonotherapy | true ⓘ |
| isNotIndicatedFor |
post-exposure prophylaxis of Ebola virus disease
ⓘ
pre-exposure prophylaxis of Ebola virus disease ⓘ |
| isProtein | true ⓘ |
| isSingleComponentProduct | true ⓘ |
| legalStatusUS | prescription-only medicine ⓘ |
| mechanismOfAction |
binds to Ebola virus glycoprotein
ⓘ
neutralizes Ebola virus entry into host cells ⓘ |
| originSpecies | Homo sapiens ⓘ |
| pharmacologicalClass | Ebola virus glycoprotein–directed monoclonal antibody ⓘ |
| reduces | mortality in Ebola virus disease patients ⓘ |
| regulatoryDesignation | orphan drug (US) ⓘ |
| regulatoryPathway | FDA approval under traditional approval pathway ⓘ |
| riskGroup | patients with confirmed Zaire ebolavirus infection ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets | Zaire ebolavirus glycoprotein ⓘ |
| therapeuticArea |
infectious diseases
ⓘ
viral hemorrhagic fevers ⓘ |
| usedFor |
treatment of Ebola virus disease
ⓘ
treatment of Zaire ebolavirus infection ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ansuvimab Description of subject: Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.